nother embarrassing and costly blunder has befallen Celgene.

The Food and Drug Administration is refusing to review ozanimod, an experimental treatment for multiple sclerosis and Celgene’s most important pipeline product, the company said Tuesday.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.